Literature DB >> 35661984

Advances in liver organoids: model systems for liver disease.

Jaeseo Lee1, Seon Ju Mun1,2, Yongbo Shin1,2, Seonbhin Lee1,2, Myung Jin Son3,4.   

Abstract

Reliable in vitro models with human-derived cells that recapitulate in vivo-like physiologies are required for drug discovery and development to reduce the gap between the results of cell-based drug testing, animal testing, and human clinical trials. Liver organoid models have emerged as novel tools for hepatotoxicity evaluation, liver disease modeling, and drug screening. Liver organoids can be generated from biopsies of liver tissues or pluripotent stem cells and can be applied to various liver diseases, including metabolic associated fatty liver disease, infectious liver disease, genetic liver disease, and liver cancer. This review focuses on recent studies on organoids to model human liver diseases and discusses the advantages and limitations of current liver organoids for translational applications.
© 2022. The Pharmaceutical Society of Korea.

Entities:  

Keywords:  Disease model; Drug screening; Liver; Organoids

Mesh:

Year:  2022        PMID: 35661984     DOI: 10.1007/s12272-022-01390-6

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  61 in total

1.  Paracrine signals regulate human liver organoid maturation from induced pluripotent stem cells.

Authors:  Akihiro Asai; Eitaro Aihara; Carey Watson; Reena Mourya; Tatsuki Mizuochi; Pranavkumar Shivakumar; Kieran Phelan; Christopher Mayhew; Michael Helmrath; Takanori Takebe; James Wells; Jorge A Bezerra
Journal:  Development       Date:  2017-03-15       Impact factor: 6.868

Review 2.  Burden of liver diseases in the world.

Authors:  Sumeet K Asrani; Harshad Devarbhavi; John Eaton; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-09-26       Impact factor: 25.083

Review 3.  Biotechnology Challenges to In Vitro Maturation of Hepatic Stem Cells.

Authors:  Chen Chen; Alejandro Soto-Gutierrez; Pedro M Baptista; Bart Spee
Journal:  Gastroenterology       Date:  2018-02-08       Impact factor: 22.682

Review 4.  Liver cancer: Approaching a personalized care.

Authors:  Jordi Bruix; Kwang-Hyub Han; Gregory Gores; Josep Maria Llovet; Vincenzo Mazzaferro
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

5.  Microbial-derived lithocholic acid and vitamin K2 drive the metabolic maturation of pluripotent stem cells-derived and fetal hepatocytes.

Authors:  Yishai Avior; Gahl Levy; Michal Zimerman; Daniel Kitsberg; Robert Schwartz; Ronen Sadeh; Arieh Moussaieff; Merav Cohen; Joseph Itskovitz-Eldor; Yaakov Nahmias
Journal:  Hepatology       Date:  2015-04-22       Impact factor: 17.425

6.  Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol.

Authors:  Yu-Fan Chen; Chien-Yu Tseng; Hsei-Wei Wang; Hung-Chih Kuo; Vincent W Yang; Oscar K Lee
Journal:  Hepatology       Date:  2012-03-01       Impact factor: 17.425

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 8.  Liver organoid as a 3D in vitro model for drug validation and toxicity assessment.

Authors:  Anastasia Brooks; Xiaowen Liang; Yonglong Zhang; Chun-Xia Zhao; Michael S Roberts; Haolu Wang; Lei Zhang; Darrell H G Crawford
Journal:  Pharmacol Res       Date:  2021-04-20       Impact factor: 7.658

9.  Merging organoid and organ-on-a-chip technology to generate complex multi-layer tissue models in a human retina-on-a-chip platform.

Authors:  Kevin Achberger; Christopher Probst; Jasmin Haderspeck; Sylvia Bolz; Julia Rogal; Johanna Chuchuy; Marina Nikolova; Virginia Cora; Lena Antkowiak; Wadood Haq; Nian Shen; Katja Schenke-Layland; Marius Ueffing; Stefan Liebau; Peter Loskill
Journal:  Elife       Date:  2019-08-27       Impact factor: 8.140

10.  Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.

Authors:  Laura Broutier; Gianmarco Mastrogiovanni; Monique Ma Verstegen; Hayley E Francies; Lena Morrill Gavarró; Charles R Bradshaw; George E Allen; Robert Arnes-Benito; Olga Sidorova; Marcia P Gaspersz; Nikitas Georgakopoulos; Bon-Kyoung Koo; Sabine Dietmann; Susan E Davies; Raaj K Praseedom; Ruby Lieshout; Jan N M IJzermans; Stephen J Wigmore; Kourosh Saeb-Parsy; Mathew J Garnett; Luc Jw van der Laan; Meritxell Huch
Journal:  Nat Med       Date:  2017-11-13       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.